TechMARK movers: Oxford Biomedica award
22nd Sep 2010 12:33
Oxford Biomedica is higher after its TroVax vaccine was chosen as one of the 10 oncology projects to watch by Windhover Information and the publishers of In Vivo and Start Up industry publications. TroVax is designed to stimulate the immune system to destroy cancer cells. A phase II study for the t
Read moreUK SMALLCAP ROUNDUP: Intec Telecom In Early Offer Talks
26th Jul 2010 16:00
Dow Jones smallcap news is now on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps INTEC TELECOM SYSTEMS PLC (ITL.LN), a billing software company, Monday said it is in very early discussions that may or may not lead to an offer for the
Read moreOxford BioMedica gets TroVax green light
26th Jul 2010 13:39
Oxford Biomedica, which has traded between 9.10p and 12p all year, bounced off the lower end of its trading range on Monday after the gene therapy company announced significant regulatory approval for its TroVax drug. The US Food and Drug Administration (FDA) and Recombinant DNA Advisory Committee
Read moreUK SMALLCAP ROUNDUP: RM Sees Scale-Back Of Pending BSF Work
26th Jul 2010 12:30
Dow Jones smallcap news is now on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps RM PLC (RM.LN) expects to find out soon if it has won six Building Schools for the Future, or BSF, projects, although the amount of work required may be
Read moreUK SMALLCAP ROUNDUP: Connaught Plunges On Funding Warning
26th Jul 2010 09:30
Dow Jones smallcap news is now on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps CONNAUGHT PLC (CNT.LN), a support services firm, warned it will breach its banking covenants when its fiscal year ends Aug. 31 and its year-end net debt
Read moreOxford BioMedica TroVax Prostate Cancer Trial Approved
26th Jul 2010 07:32
LONDON (Dow Jones)--Biotechnology company Oxford BioMedica PLC (OXB.LN) Monday said it received approval to begin a clinical trial of its cancer vaccine TroVax in men with prostate cancer. Oxford BioMedica said the U.S. Food and Drug Administration approved plans to begin a Phase II trial of Tro
Read moreTechMARK movers: New grant for Oxford Biomedica
1st Jul 2010 13:11
Gene therapies developer Oxford Biomedica is higher following an R&D presentation for investors. It is also part of a collaborative research project that will receive a £255,000 grant from the UK Motor Neurone Disease Association for the further evaluation of MoNuDin® for the treatment of amyotrophi
Read moreUK SMALLCAP ROUNDUP: ABB Drops Chloride Bid
1st Jul 2010 09:30
Dow Jones smallcap news is now on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps ABB LTD. (ABB), a Swiss engineer, Thursday threw in the towel in a bidding war over U.K. industrial company CHLORIDE GROUP PLC (CHLD.LN), increasing the
Read moreOxford BioMedica Gets Grant To Test Lou Gehrig's Disease Drug
1st Jul 2010 07:56
LONDON (Dow Jones)--Biotechnology company Oxford BioMedica PLC (OXB.LN) Thursday said it received a grant from a charity to fund early-stage development of an experimental drug for amyotrophic lateral sclerosis, a form of motor neurone disease commonly known as Lou Gehrig's disease. Oxford BioMe
Read moreUK SMALLCAP ROUNDUP: Hong Kong's MiLOC Group Plans AIM IPO
24th Jun 2010 12:30
Dow Jones smallcap news is now on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps MILOC GROUP, a Hong Kong-based healthcare company, is planning an initial public offering in London to raise funds to establish a network of traditional
Read moreUK SMALLCAP ROUNDUP: DS Smith Eyes Less Cyclical Business
24th Jun 2010 09:30
Dow Jones smallcap news is now on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps DS SMITH PLC (SMDS.LN), a packaging company, Thursday said it is targeting higher returns and less cyclical business as part of a major company review.
Read moreMARKET TALK: Ambrian Starts Oxford BioMedica At Buy
24th Jun 2010 08:23
0723 GMT [Dow Jones] Ambrian initiates coverage of Oxford BioMedica (OXB.LN) with a buy rating, and fair value of 24p. Analyst Chris Redhead is confident the biotechnology company can secure a deal for its experimental Parkinson's disease treatment ProSavin within nine months. Adds investors can als
Read moreUK MARKET TALK ROUNDUP: BROKERS COMMENTS
24th Jun 2010 08:23
Broker comments in the UK today. Compiled by Dow Jones Newswires Markets Desk, [email protected] Contact us in London. +44-20-7842-9464 [email protected] 0723 GMT [Dow Jones] Ambrian initiates coverage of Oxford BioMedica (OXB.LN) with a buy rating, and fair value of 24p. Analys
Read moreOxford BioMedica's TroVax To Be Tested In Asbestos Cancer
24th Jun 2010 07:50
LONDON (Dow Jones)--Biotechnology company Oxford BioMedica PLC (OXB.LN) Thursday said it has teamed up with scientists in Wales to test its experimental cancer vaccine TroVax in patients with mesothelioma, a cancer of the lung lining linked to exposure to asbestos. Oxford BioMedica said it enter
Read moreTechMARK movers: Oxford Biomedica amends antigen licence
18th Jun 2010 14:46
Gene therapy company Oxford Biomedica has agreed an amendment to its licence with Cancer Research Technology covering the 5T4 antigen used in the Tro-Vax cancer vaccine. The deal covers royalties due to CRT relating to the sanofi-aventis TroVax agreement (signed March 2007 and terminated April 200
Read more